BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3922688)

  • 1. Determination of middle molecules in uremic patients.
    Wu ZG; Cai ZH; Lu ZN; Liao LT; Zhu SQ
    Chin Med J (Engl); 1985 Feb; 98(2):115-20. PubMed ID: 3922688
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acid-base equilibrium in uremia: effect of continuous ambulatory peritoneal dialysis and hemodialysis].
    Nin Ferrari J; Santoro A; Fabbri L; Cavilli F; Zucchelli P
    G Clin Med; 1981 Sep; 62(9):624-33. PubMed ID: 7319174
    [No Abstract]   [Full Text] [Related]  

  • 3. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of continuous ambulatory peritoneal dialysis on anemia in uremic patients.
    Marcovici O; Boner G; Rosenfeld JB
    Isr J Med Sci; 1983 Jul; 19(7):604-7. PubMed ID: 6885343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiamine blood level and erythrocyte transketolase activity in continuous ambulatory peritoneal dialysis and intermittent peritoneal dialysis patients.
    Pietrzak I; Baczyk K; Ksiazek P
    Ann Univ Mariae Curie Sklodowska Med; 1995; 50():197-203. PubMed ID: 9263507
    [No Abstract]   [Full Text] [Related]  

  • 7. [Polycentric analysis of the behavior of uremic patients undergoing dialysis].
    Figus S; Zammit A; Bordoni E; Mioli V; Capobianco P; Martarelli D; Cecchini F; De Jasi A; Capponi E; Panichi N; Castelli F; Concetti M
    Minerva Nefrol; 1982; 29(4):215-21. PubMed ID: 7155441
    [No Abstract]   [Full Text] [Related]  

  • 8. Separation and characterization of uremic metabolites in biologic fluids: a screening approach to the definition of uremic toxins.
    Gordon A; Berström J; Fürst P; Zimmerman L
    Kidney Int Suppl; 1975 Jan; (2):45-51. PubMed ID: 1057692
    [No Abstract]   [Full Text] [Related]  

  • 9. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodialysis, continuous ambulatory peritoneal dialysis and cellular immunity.
    Collart F; Tielemans C; Dratwa M; Schandene L; Wybran J; Dupont E
    Proc Eur Dial Transplant Assoc; 1983; 20():190-4. PubMed ID: 6228939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic middle molecules.
    Bergström J; Fürst P
    Clin Nephrol; 1976 Apr; 5(4):143-52. PubMed ID: 1277596
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous ambulatory peritoneal dialysis improves immunodeficiency in uremic patients.
    Giacchino F; Quarello F; Pellerey M; Piccoli G
    Nephron; 1983; 35(3):209-10. PubMed ID: 6633764
    [No Abstract]   [Full Text] [Related]  

  • 13. [Retention of medium sized molecules in uremic serum].
    Dall'aglio P; Buzio C; Cambi V; Arisi L; Migone L
    Proc Eur Dial Transplant Assoc; 1972; 9():409-16. PubMed ID: 4668919
    [No Abstract]   [Full Text] [Related]  

  • 14. The influence of larger molecules on cellular response in uremia.
    Giacchino F; Quarello F; Pozzato M; Giraudo G; Formica M; Quattrocchio G; Piccoli G
    Trans Am Soc Artif Intern Organs; 1983; 29():29-32. PubMed ID: 6608816
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pulmonary function in uremic patients treated with continuous ambulatory peritoneal dialysis (CAPD)].
    Gómez Fernández P; Miguel Alonso JL; Sánchez Agudo L; Calatrava JM; Conesa J; Sánchez Sicilia L
    Med Clin (Barc); 1982 Sep; 79(5):219-23. PubMed ID: 7144303
    [No Abstract]   [Full Text] [Related]  

  • 16. Middle molecules in uraemia.
    Fürst P; Asaba M; Gordon A; Zimmerman L; Bergström J
    Proc Eur Dial Transplant Assoc; 1975; 11():417-26. PubMed ID: 1105558
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of chronic uremia by dialysis].
    Lampainen E
    Duodecim; 1983; 99(17):1218-26. PubMed ID: 6357721
    [No Abstract]   [Full Text] [Related]  

  • 18. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P; Zimmerman L; Bergström J
    Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous ambulatory peritoneal dialysis (CAPD).
    Swartz RD
    Compr Ther; 1983 Aug; 9(8):54-60. PubMed ID: 6617129
    [No Abstract]   [Full Text] [Related]  

  • 20. [Uremic neuropathy and the type of dialysis].
    Firenze C; Gallai V; Mattelli L; Mazzotta G; Panzetta AM; Buoncristiani U
    Riv Patol Nerv Ment; 1982; 103(6):271-6. PubMed ID: 6326249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.